Menlo Park, CA, December 4, 2012 – Corium International, Inc. (“Corium”) and Capital Royalty Partners II, L.P. (“Capital Royalty”) announced that they have closed a term loan facility for up to $35 million of capital. Corium is a privately-held transdermal drug delivery company with a strong track record of successful development and manufacture of advanced pharmaceutical products. Corium intends to use the proceeds to refinance its outstanding debt, support corporate growth initiatives, and execute on its strategic plan.
“We are excited to have the support of Capital Royalty through their strategic investment and we are extremely pleased with our…Read More »
-- Highly-customized financing provides $20 million in growth capital to innovative life sciences company --
Houston, TX – May 1, 2012 – Effective April 10, 2012, Capital Royalty Partners II, L.P. and its parallel investment vehicles (“Capital Royalty”) entered into a $20 million term loan and revenue interest financing agreement with Bioniche Life Sciences Inc. (“Bioniche”) (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company (“Bioniche”).
Under the terms of the agreement, Capital Royalty provided Bioniche a five-year $20 million loan, with proceeds from the financing intended to support corporate growth initiatives across Bioniche’s three primary business…Read More »